News

Hospira chief scientific officer returns

BY Alaric DeArment

LAKE FOREST, Ill. — Hospira has reappointed its chief scientific officer after he briefly left the country earlier this year, the generic drug maker said.

Sumant Ramachandra has been reappointed to the position, effective Friday, and will be in charge of the company’s research and development, regulatory and medical affairs.

"Under Sumant’s leadership, Hospira has established one of the most robust biosimilars pipelines in the industry, expanded an already market-leading generic injectables portfolio and built a talented scientific, medical and regulatory organization to execute our vision for future success. While we had interviewed an exceptional slate of candidates for this role, we determined that Sumant remained not only the best fit, but also would be best positioned to seamlessly advance our R&D priorities."

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

FDA advisory committee to meet in July on opioid painkiller

BY Alaric DeArment

SYDNEY — A Food and Drug Administration panel will consider whether to recommend approval for an experimental painkiller in July, the drug’s developer said Friday.

Australia-based QRxPharma said the FDA had determined that an advisory committee would meet on July 17 to consider a resubmitted application for Moxduo, an immediate-release formulation of the opioid painkillers morphine and oxycodone.

The company has sought approval for the drug since summer 2011, and the FDA has indicated it will decide whether or not to approve it in August 2013. The agency is not required to follow advisory committee recommendations in deciding whether or not to approve a drug, but usually does.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

New vitamin-based anti-aging serum hits market

BY Antoinette Alexander

BOISE, Idaho — Epionce has announced the launch of Intense Defense Anti-Aging + Repair Serum, which it is positioning as the first complete multivitamin for the skin.

The serum is designed to stimulate skin rejuvenation using botanical sources of vitamins A, B, C, D and E without irritation.

In an independent clinical study, Epionce Intense Defense Serum was tested against Skin Medica TNS Recovery Complex serum and Skinceuticals CE Ferulic serum. The Intense Defense Serum was proven to diminish signs of visible aging faster than the other two serums, and with far better tolerability, according to the manufacturer.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?